ADAMTS13 and Sepsis: In 2007, two studies showed that serum levels of ADAMTS13 were lower in severe sepsis and septic shock, but had mixed evidence of mortality effects.39, 40More recently, multiple studies demonstrated that patients with COVID-19 pneumonia have reduced levels of ADAMTS13, causing a microangiopathic thrombotic state41, 42and leading to associations with worsened mortality.36, 43, 44Our study corroborates that ADAMTS13 deficiency was associated with mortality, but it failed to identify those patients with increased risk of hematologic events.